- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
The Rationale for Immunotherapy in NSCLC
Heather Wakelee, MD
Special Reports, Immunotherapy (Issue 5), Volume 5, Issue 1
Heather Wakelee, MD, associate professor of medicine, oncology division, Stanford University, discusses the rationale for immunotherapy in non-small cell lung cancer (NSCLC).
Heather Wakelee, MD, associate professor of medicine, oncology division, Stanford University, discusses the rationale for immunotherapy in non-small cell lung cancer (NSCLC).
<<<